Senti Biosciences, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Nantahala Capital Partners Limited Partnership has filed an amended Schedule 13G, reporting a beneficial ownership of 1.9% in Senti Biosciences, Inc. as of March 31, 2025.
NASDAQ
Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has disclosed an 8.12% beneficial ownership stake in Senti Biosciences, Inc., including shares acquirable via warrants.
NASDAQ
Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has disclosed an 8.12% beneficial ownership stake in Senti Biosciences, Inc., including shares acquirable via warrants.
NASDAQ
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, disclosing a passive beneficial ownership of 4.99% in Senti Biosciences, Inc.'s Class A Common Stock as of March 31, 2025.
NASDAQ
8VC Fund I, L.P., 8VC Entrepreneurs Fund I, L.P., 8VC GP I, LLC, and Joe Lonsdale have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 253,755 shares, representing 1% of Senti Biosciences, Inc.'s common stock.
NASDAQ
SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose Significant 9.99% Stake in Senti Biosciences
Armistice Capital, LLC and Steven Boyd have jointly disclosed a 9.99% beneficial ownership stake in Senti Biosciences, Inc.'s Class A Common Stock, held for investment purposes.
NASDAQ
Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has disclosed a 9.99% beneficial ownership stake in Senti Biosciences, Inc. as of December 31, 2024.
NASDAQ
Nantahala Capital Partners Limited Partnership has reported a 5.914% beneficial ownership stake in Senti Biosciences, Inc., primarily through shares acquirable via warrants.